11-17-10 WEDNESDAY STKINFO.COM

FIRST CALL

MSNBC NEWS

WEDNESDAY NOVEMBER 17 2010

NEWS RESEARCH SECTORS NEWSPAPERS SUNDAY BARRONS

STKINFO TOP LINKS:

Seeking Alpha

Stock Quote

TownHall.com Columnists

WEATHER

The World Clock
statistical data

Dictionary

	Acronyms
	Bonds
	Buzz Words
	Fundamental Anly
	Mutual Funds
	New Economy
	Options & Futures
	Real Estate
	Retirement
	Stock Trading
	Taxes
	Tech Analysis
	World Markets Stock Market Glossary

ARCHIVED STKINFO.COM
click refresh to update

Economic
07:00 MBA Mortgage Applications: +5.8% prior
08:30 CPI (Oct.): 0.3% cons.
08:30 Core CPI (Oct.): 0.1% cons.
08:30 Housing Starts (Oct.): 600K cons.
08:30 Building Permits (Oct.): 565K cons.
10:30 Crude Inventories: -3.27M prior

TOP FINANCIAL NEWS

Stocks dragged lower by global worries

DYN Dynegy: Icahn remains opposed to proposed Blackstone acquisition of Dynegy at $5.00 Per Share

Carl Icahn today released this statement, indicating that he will be voting against the proposed acquisition of Dynegy by Blackstone, including the following reasons: "I believe that, even at $5.00 per share, the proposed Blackstone acquisition undervalues Dynegy. Today's $.50 per share increase, coming only one day after Blackstone stated that the $4.50 price is "a full and fair valuation" reassures my belief that the Dynegy/Blackstone transaction leaves too much shareholder value on the table for Blackstone. I have also considered that in a November 15, 2010 report JP Morgan stated that it is "introducing a December 2011 price target of $7, up from our prior December price target of $5.00."

BUSINESS NEWS

HGSI FDA Panel Backs
Lupus Drug

After Hours Summary
STV +8.4%, SINA -3.4% Following Earnings; HGSI +9.2% (FDA Panel votes 13-2 positive recommending that Benlysta be approved), POT -1.0% (announces $2 bln share repurchase program)

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings

STV +8.4%, GFA +1.8%.

Companies trading higher in after hours in reaction to news:

HGSI +9.2% (FDA Panel votes 13-2 positive recommending that Benlysta be approved; Human Genome Sciences and GlaxoSmithKline(GSK) announce vote of FDA advisory committee to recommend approval of BENLYSTA for systemic Lupus Erythematosus, CMA +3.4% (increases the quarterly cash dividend for common stock to $0.10 per share and authorizes purchase of 12,576,281 shares), DYN +1.4% (Dynegy: Icahn remains opposed to proposed Blackstone acquisition of Dynegy at $5.00 Per Share), POT -1.0% (announces US$2 bln share repurchase program).

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: SINA -3.4%.